Immune-Boosting drug combo takes on Hard-to-Treat ovarian cancer
NCT ID NCT05114421
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This pilot study tests two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted enzyme blocker)—in women with platinum-resistant high-grade serous ovarian, fallopian tube, or peritoneal cancer. The goal is to see how these drugs, given alone and together, change immune cells inside tumors. The study enrolls about 30 participants and aims to find a more effective way to control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and lenvatinib
- What this could lead to
- If successful, this could point toward a new treatment option for platinum-resistant ovarian cancer by boosting the immune system's ability to fight tumors.
- What could go wrong
- This is a small, early-phase pilot study, so results may not apply broadly. The combination may cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine combo shows promise in ovarian cancer fight
- New antibody combo takes on Hard-to-Treat cancers
- New drug shows promise in shrinking ovarian tumors before surgery
- New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
- New combo therapy targets Hard-to-Treat recurrent cancers
- New drug cocktail shows promise for Hard-to-Treat ovarian cancer